CJC-1295 without DAC

CJC-1295 without DAC is a modified GHRH(1-29) analog with four amino acid substitutions for enhanced enzymatic stability. It is functionally identical to mod GRF 1-29 — the names refer to the same compound. The "without DAC" designation distinguishes it from the longer-acting CJC-1295 with DAC, which adds an albumin-binding tether for 6–8 day half-life. CJC-1295 without DAC is not approved for any medical indication and is sold as a research-use-only compound.

What is CJC-1295 without DAC and how does the modified GHRH(1-29) mechanism work?

CJC-1295 without DAC is sermorelin (GHRH(1-29)) with four amino acid substitutions — D-Ala at position 2, Gln at position 8, Ala at position 15, Leu at position 27 — that confer resistance to DPP-4 degradation and enhance binding stability. "CJC-1295 without DAC" and "Mod GRF 1-29" are two names for the same molecule: a stabilized GHRH(1-29) fragment with no Drug Affinity Complex. It is distinct from CJC-1295 with DAC, which adds an albumin-binding tether that extends the half-life from minutes to days — the two are not interchangeable, and lab certificates for one do not validate the other. The result is a moderately extended half-life (~30 minutes) compared to native sermorelin (~10–20 min) while preserving GHRH receptor agonist activity. It produces pulsatile GH release similar to native GHRH, supporting multiple-daily-dose research protocols.

Evidence level: preclinical and Phase 1 PK; no published Phase 2/3 efficacy trials in any indication

What does the research show for CJC-1295 without DAC?

Phase 1 pharmacokinetic studies confirm dose-dependent GH and IGF-1 elevation with subcutaneous administration, with peak GH response at approximately 1 hour and return to baseline by 3–4 hours. No published Phase 2 or Phase 3 efficacy trials for any indication exist as of August 2026. The compound is essentially identical to mod GRF 1-29 in pharmacological terms; the dual-naming convention persists in research-grade catalogs largely for historical reasons.

Evidence level: phase 1 PK; no Phase 2/3 efficacy data

How does CJC-1295 without DAC compare to CJC-1295 with DAC?

The two compounds share the same GHRH(1-29) sequence with the four stability substitutions; CJC-1295 with DAC adds a maleimidopropionic acid (DAC) tether that covalently binds to serum albumin, extending half-life from ~30 minutes to ~6–8 days. This produces very different dosing strategies and GH-release dynamics.

What are the documented side effects of CJC-1295 without DAC?

Side effects in available Phase 1 data and community-reported research use are mild — injection-site reactions, occasional transient flushing, mild headache. The pulsatile GH-release pattern means cortisol and prolactin effects are minimal (it is a pure GHRH analog, not a ghrelin-receptor GHS). IGF-1 elevation is dose-dependent and reversible with discontinuation. Long-term safety at sustained research-use dosing is not well-characterized given the absence of completed long-duration trials.

Evidence level: phase 1 safety data; long-term unestablished

What is the regulatory status of CJC-1295 without DAC?

CJC-1295 without DAC is not approved for any medical indication anywhere in the world as of August 2026. Its nomination to the FDA's 503A compounding list was withdrawn by the nominators, so — unlike the six peptides the FDA advisory committee recommended in July 2026 — CJC-1295 was not among them and remains unauthorized for pharmacy compounding. It is sold strictly as a research-use-only compound by third-party laboratories. No active clinical development program is currently advancing. Regulatory context in are peptides legal regulatory status by country.

Source: FDA Announces Removal of 12 Peptides from Category 2 (nominations withdrawn by the nominators) and Schedules PCAC Meetings, Orrick (legal analysis of the FDA notice), via Orrick Insights

Why does CJC-1295 without DAC vendor verification matter?

Because the compound is one of the most widely-sold research-grade GHRH analogs and quality variance across vendors is substantial — and because mod GRF 1-29 and CJC-1295 without DAC are the same molecule sold under different names, buyers should verify they're getting the correct compound regardless of which label the vendor uses. Independent HPLC purity testing and mass spectrometry identity confirmation are the meaningful purity signals. Guidance in how-to-test-peptides hub.

How does Peptigrity verify CJC-1295 without DAC vendors?

Peptigrity collects independent third-party Certificates of Analysis for CJC-1295 without DAC from shops' official channels and verifies each for authenticity before publishing. Because shops choose which COAs to publish, results reflect the batches shops have made public rather than every production batch — a selection bias we state openly. A community-funded Testing Grant to purchase and test vials anonymously is in development. The lab test table above this section shows the cross-shop dataset. Tests come from labs including Janoshik Analytical, Freedom Diagnostics, and Chromate. Methodology in how we calculate trust scores.

Frequently asked questions

Is CJC-1295 without DAC the same as mod GRF 1-29?

Yes. CJC-1295 without DAC and mod GRF 1-29 are the same compound — GHRH(1-29) with four amino acid substitutions for stability. The dual-naming convention persists in research-grade catalogs for historical reasons. Buyers should not pay for "stacking" both names.

Is CJC-1295 without DAC legal to purchase?

CJC-1295 without DAC is legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is not approved for human consumption. Country breakdown in peptide legal status guide.

How can I verify a CJC-1295 without DAC vendor is selling real product?

Independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay, with mass spectrometry identity confirmation. Mass-spectrometry identity confirmation is essential: it separates CJC-1295 without DAC from the heavier DAC-conjugated form (which carries an albumin-binding maleimidopropionic-acid tether) and from sermorelin, all of which look similar on HPLC alone. COA interpretation in red flags in peptide certificates of analysis.

How does CJC-1295 without DAC compare to ipamorelin?

Different mechanisms — CJC-1295 without DAC is a GHRH analog (acts on GHRH receptor), ipamorelin is a ghrelin-receptor agonist (acts on GHS-R1a). They engage different pituitary signaling pathways and are commonly studied in combination in research protocols to amplify GH release through complementary mechanisms.

Will CJC-1295 without DAC be FDA-approved?

No active clinical development program exists as of August 2026. FDA approval is unlikely without a renewed development effort.

Does Peptigrity recommend a CJC-1295 without DAC dose?

No. CJC-1295 without DAC is not approved for human consumption and Peptigrity is an independent review platform, not a medical authority. Research-use dosing in community protocols varies widely. Anyone considering use should consult a licensed physician.

This section is for educational and informational purposes only and does not constitute medical advice. CJC-1295 without DAC is not approved by the FDA or any other regulator for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.